The expression profile and tumorigenic mechanisms of CD97 (ADGRE5) in glioblastoma render it a targetable vulnerability

Abstract excerpt

Glioblastoma (GBM) is the most common and aggressive primary brain malignancy. Adhesion G protein-coupled receptors (aGPCRs) have attracted interest for their potential as treatment targets. Here, we show that CD97 (ADGRE5) is the most promising aGPCR target in GBM, by virtue of its de novo expression compared to healthy brain tissue. CD97 knockdown or knockout significantly reduces the tumor initiation capacity...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer, Stress, Anesthesia, and Immune Response
• Share to Neuroscience and Neuropharmacology Research
• Share to Receptor Mechanisms and Signaling